+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spinal Muscular Atrophy Market Global Forecast by Countries, Drugs, and Companies

  • ID: 4674449
  • Report
  • November 2018
  • Region: Global, United Kingdom, United States, Germany, France, Italy, Japan, Spain
  • 121 Pages
  • Renub Research
1 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics Inc
  • Novartis AG
  • Roche AG
  • MORE

Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally. Spinal muscular atrophy is basically 4 types - Type 1, Type 2, Type 3 and type 4. Most patients suffer from Spinal muscular atrophy type 1. According to this research Global Spinal Muscular Atrophy (SMA) market is anticipated to grow at a CAGR of 14.29 percent in future. This double-digit growth rate will happen due to the expected launch of new drugs, better reimbursement options and a decline in drugs prices.

Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in a position to sit in their lifetime and normally they die within 6 months. In spinal muscular atrophy type 2, patients can sit but cannot walk. Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during adulthood.

This report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years

At present only Biogen’s Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc. Other companies are also working for new drugs development and they hope to enter in the marketplace very soon as their drugs are in Phase III clinical trials.

By Country - Market Segmentation

Spinal muscular atrophy market by country has been segmented into the United States, United Kingdom, France, Germany, Spain, Italy, and Japan. United States is a leading marketplace due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure.

By Total & Treated Patients - Population Segmentation

Spinal muscular atrophy Total & Treated Patients by country has been segmented into the United States, United Kingdom, France, Germany, Spain, Italy, and Japan. United States is dominating in the treated SMA patients globally.

By Drugs - Market Segmentation

The studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales.

The Report has been analyzed from 9 Major Viewpoints
1. Global Spinal Muscular Atrophy Market (Present & Forecast)
2. Global Spinal Muscular Atrophy Market Share, Patients Share, Treated Patients Share (Present & Forecast)
3. Country Spinal Muscular Atrophy Market (Present & Forecast)
4. Country Spinal Muscular Atrophy Patients Population (Present & Forecast)
5. Country Spinal Muscular Atrophy Treated Patients Population (Present & Forecast)
6. Spinal Muscular Atrophy Drugs Sales (Present & Forecast)
7. Global - Clinical Study on Spinal Muscular Atrophy & Drugs Pipeline
8. Growth Drivers and Challenges
9. Key Spinal Muscular Atrophy Companies Initiatives and Financial Insight

Country Covered in this Report

  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Japan

Drugs Details Covered in this Report

  • Spinraza
  • AVXS-101
  • CK2127107
  • RG7916
  • Olesoxime
  • LMI070

Company Covered in this Report

  • Biogen Inc.
  • Roche AG
  • Novartis AG
  • Cytokinetics Inc
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics Inc
  • Novartis AG
  • Roche AG
  • MORE

1. Introduction
1.1 Market Definition
1.2 Currency Conversion

2. Research Methodology

3. Executive Summary

4. Global Spinal Muscular Atrophy Market and Patients Analysis
4.1 Spinal Muscular Atrophy Market
4.2 Spinal Muscular Atrophy Patient Numbers
4.3 Spinal Muscular Atrophy Treated Patient Number

5. Share Analysis - Global Spinal Muscular Atrophy
5.1 Country Market Share
5.2 Patients Population Share
5.3 Treated Patients Share

6. United States
6.1 Spinal Muscular Atrophy Market
6.2 Spinal Muscular Atrophy Patient Numbers
6.3 Spinal Muscular Atrophy Treated Patients

7. United Kingdom
7.1 Spinal Muscular Atrophy Market
7.2 Spinal Muscular Atrophy Patient Numbers
7.3 Spinal Muscular Atrophy Treated Patient Numbers

8. Germany
8.1 Spinal Muscular Atrophy Market
8.2 Spinal Muscular Atrophy Patient Numbers
8.3 Spinal Muscular Atrophy Treated Patients

9. Italy - Spinal Muscular Atrophy
9.1 Spinal Muscular Atrophy Market
9.2 Spinal Muscular Atrophy Patient Numbers
9.3 Spinal Muscular Atrophy Treated Patient Numbers

10. France - Spinal Muscular Atrophy
10.1 Spinal Muscular Atrophy Market
10.2 Spinal Muscular Atrophy Patient Numbers
10.3 Spinal Muscular Atrophy Treated Patient Numbers

11. Spain
11.1 Spinal Muscular Atrophy Market
11.2 Spinal Muscular Atrophy Patient Numbers
11.3 Spinal Muscular Atrophy Treated Patient Numbers

12. Japan
12.1 Spinal Muscular Atrophy Market
12.2 Spinal Muscular Atrophy Patients
12.3 Spinal Muscular Atrophy Treated Patient Numbers

13. Drugs Sales - Spinal Muscular Atrophy
13.1 Spinraza
13.2 AVXS-101
13.3 CK2127107
13.4 RG7916
13.5 Olesoxime
13.6 LMI070

14. Spinal Muscular Atrophy Study Status Analysis
14.1 Spinal Muscular Atrophy Clinical Study
14.2 Spinal Muscular Atrophy Drugs Development Pipeline

15. Growth Drivers
15.1 Increasing Funding for Research & Development
15.2 Biogen Access Programs

16. Challenges
16.1 High Treatment Cost
16.2 Common Side Effects

17. Biogen Inc.
17.1 Business Overview
17.2 Initiatives/Strategies
17.2.1 Point 1
17.2.2 Point 2
17.2.3 Point 3
17.3 Financial Insight

18. Novartis AG
18.1 Business Overview
18.2 Initiatives/Strategies
18.2.1 Point 1
18.2.2 Point 2
18.3 Financial Insight

19. Roche Holding AG
19.1 Business Overview
19.2 Initiatives/Strategies
19.2.1 Point 1
19.2.2 Point 2
19.3 Financial Insight

20. Cytokinetics, Inc.
20.1 Business Overview
20.2 Initiatives/Strategies
20.2.1 Point 1
20.2.2 Point 2
20.3 Financial Insight

List of Figures
Figure 2-1: Global - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 2-2: Global - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 2-3: Global - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 3-1: Global - Current & Forecast for Spinal Muscular Atrophy Market Share (Percent), 2017 - 2026
Figure 3-2: Global - Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 - 2026
Figure 3-3: Global - Current & Forecast for Spinal Muscular Atrophy Treated Patients Share (Percent), 2017 - 2026
Figure 4-1: United States - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 4-2: United States - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 4-3: United States - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 5-1: United Kingdom - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 5-2: United Kingdom - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 5-3: United Kingdom - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 6-1: Germany - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 6-2: Germany - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 6-3: Germany - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 7-1: Italy - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 7-2: Italy - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 7-3: Italy - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 8-1: France - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 8-2: France - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 8-3: France - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 9-1: Spain - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 9-2: Spain - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 9-3: Spain - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 10-1: Japan - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
Figure 10-2: Japan - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
Figure 10-3: Japan - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
Figure 11-1: Global - Current & Forecast for Spinraza Sales (Million US$), 2017 - 2026
Figure 11-2: Global - Current & Forecast for AVXS-101 Sales (Million US$), 2017 - 2026
Figure 11-3: Global - Current & Forecast for CK212710 Sales (Million US$), 2022 - 2026
Figure 11-4: Global - Current & Forecast for RG7916 Sales (Million US$), 2024 - 2026
Figure 11-5: Global - Current & Forecast for LMI070 Sales (Million US$), 2021 - 2026
Figure 12-1: Spinal Muscular Atrophy Drugs Development Pipeline, September 2018
Figure 15-1: Biogen - Global Sales (Million US$), 2013 - 2017
Figure 15-2: Biogen - Forecast for Global Sales (Million US$), 2018 - 2026
Figure 16-1: Novartis - Global Sales (Million US$), 2013 - 2017
Figure 16-2: Novartis - Forecast for Global Sales (Million US$), 2018 - 2026
Figure 17-1: Roche - Global Sales (Million US$), 2013 - 2017
Figure 17-2: Roche - Forecast for Global Sales (Million US$), 2018 - 2026
Figure 18-1: Cytokinetics - Global Sales (Thousand US$), 2013 - 2017

List of Tables
Table 12 1: Global - Spinal Muscular Atrophy Clinical Study Status, 2018

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Biogen Inc.
  • Cytokinetics Inc
  • Novartis AG
  • Roche AG
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll